影响广泛阶段小细胞肺癌生存率和预后的因素
Mert Erciyestepe1, Ömer Burak Ekinci2, Hale Gülçin Yıldırım Doğan2
1Department of Medical Oncology, Sağlık Bilimleri University, Prof. Dr. Cemil Taşcıoğlu City Hospital, Darülaceze Cad. No:27, İstanbul, Turkey. merterciyestepe@gmail.com.
BMC pulmonary medicine
|April 8, 2025
概括
扩展阶段的小细胞肺癌 (ES-SCLC) 治疗可以通过阿特佐利祖马布和预防性部辐射 (PCI) 得到改善. 这些疗法显著提高整体存活率 (OS) 并降低ES-SCLC患者的死亡风险.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
- 临床试验 临床试验
背景情况:
- 扩散性小细胞肺癌 (ES-SCLC) 的复发率很高,两年生存率很差.
- 预防性头骨辐射 (PCI) 改善了响应患者的生存率.
- 像阿特佐利祖马布这样的PD-L1抑制剂在一线治疗中增强化疗的疗效.
研究的目的:
- 追溯评估治疗方式对ES-SCLC总生存期 (OS) 和无进展生存期 (PFS) 的影响.
- 分析化疗,PD-L1抑制剂和放射治疗在ES-SCLC治疗中的有效性.
主要方法:
- 在2009年7月至2023年2月期间接受治疗的280名ES-SCLC患者的回顾性分析.
- 基于化疗方案 (cisplatin+etoposide vs. carboplatin+etoposide),加上阿特佐利祖马布,循环数和放射治疗 (胸部残留放射治疗和PCI) 的生存结果的比较.
主要成果:
- 胸部残留放射治疗和PCI显著改善了OS (p<0.001).
- 在一线治疗中,卡博普拉丁+埃托普赛德+阿特佐利祖马布的平均寿命为35.0个月 (p<0.001),而卡博普拉丁+埃托普赛德的平均寿命为7.0个月,西斯普拉丁+埃托普赛德的平均寿命为12.0个月.
- 超过4次的第一线治疗和PCI周期与改善的生存状况和降低的死亡风险有关. 在诊断时,PFS在骨,肝脏或大脑转移方面变得更糟.
结论:
- 尽管如此,ES-SCLC仍然是一个具有挑战性的恶性瘤,存活率不佳.
- 治疗策略包括一线治疗阿特佐利祖马布,二线治疗西斯普拉丁+埃托普西德和PCI,可显著改善存活率并降低死亡率.
- 治疗周期数和放射治疗应用是影响患者结果的可修改因素.
相关概念视频
01:21Cancer Survival Analysis
308
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
308
02:53Adaptive Mechanisms in Cancer Cells
5.6K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.6K
02:17The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K